Please login to the form below

Not currently logged in

Pharma stocks rise after Donald Trump's election win

But his exact healthcare and industry-focus remain uncertain

US president-elect Donald Trump 

Pharmaceutical shares have surged in Europe following Donald Trump's shock victory in the US presidential elections as fears ebbed of a crackdown on prices.

GlaxoSmithKline, AstraZeneca and Shire were among the beneficiaries as major companies saw stock rises of between 2% and more than 6%.

That followed the Republican president-elect's defeat of rival Hillary Clinton, who had repeatedly criticised pharma pricing.

Nevertheless, there remains much uncertainty about Trump's exact position on the industry and healthcare in general.

He has previously noted that drug companies provide a public service and said he would “remove barriers to entry into free markets for drug providers that offer safe, reliable and cheaper products”. 

His current position on pharma states: “Congress will need the courage to step away from the special interests and do what is right for America.” 

Moreover, Trump's aggressive stance on American's trade deals, which he has promised to renegotiate, could have serious repercussions for the industry.

Where there is certainty is in Trump's critical attitude towards the Affordable Care Act for its “runaway costs, websites that don't work, greater rationing of care, higher premiums, less competition and fewer choices”.

The Act, often referred to as Obamacare, extended medical insurance coverage to around 32 million uninsured Americans and involved a major expansion of the Medicaid programme.

At its heart was the introduction of an 'individual mandate', requiring all Americans to buy a minimum level of health insurance from 2014 or be subject to a fine.

In contrast Trump's plan is to repeal the Act and “bring much-needed free market reforms to the healthcare industry”.

In its stead he has promised to improve healthcare access, affordability and quality of the care, the latter by harnessing free market principles.

He has also suggested increasing competition in the health insurance market and establishing tax-free Health Savings Accounts for individuals to pay for their care.

Alongside Trump's win in the US presidential elections the Republicans continue to control the Senate and House of Representatives, giving them a chance to break the gridlock that hampered the current administration. 

That saw Democrat Barak Obama's second term of office hamstrung by a Republican-controlled house and then, from 2015, a Republican majority Senate as well.

Article by
Dominic Tyer

9th November 2016

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...